

Title (en)

Liquid stabilized protein formulations in coated pharmaceutical containers

Title (de)

Stabilisierte Flüssige Protein Zubereitungen in beschichteten pharmazeutischen Behältnissen

Title (fr)

Compositions liquides de protéines stabilisées dans des récipients pharmaceutiques avec revêtement

Publication

**EP 2324845 A1 20110525 (EN)**

Application

**EP 11152658 A 20040512**

Priority

- EP 04760770 A 20040512
- EP 03010671 A 20030513
- EP 11152658 A 20040512

Abstract (en)

A container comprising a closure means coated by an inert fluorinated material and containing a liquid pharmaceutical composition. In particular, the container comprises a closure means coated by TEFILON and contains a HSA-free Interferon- $\alpha$  formulation having the following composition: 30 to 100  $\mu\text{g}/\text{ml}$  of interferon- $\alpha$ , an isotonicity agent, 0.1 to 2  $\text{mg}/\text{ml}$  of Poloxamer 188, at least 0.12  $\text{mg}/\text{ml}$  of L-Methionine and a buffer solution capable of maintaining the pH of the liquid formulation at a value between 3.0 and 4.0.

IPC 8 full level

**A61K 38/21** (2006.01); **A61J 1/00** (2006.01); **A61J 1/14** (2006.01); **A61K 47/10** (2006.01); **A61K 47/18** (2006.01); **A61K 47/26** (2006.01)

CPC (source: EP KR US)

**A61K 9/0019** (2013.01 - US); **A61K 38/21** (2013.01 - KR); **A61K 38/215** (2013.01 - EP US); **A61K 47/50** (2017.07 - KR);  
**A61P 37/02** (2017.12 - EP); **B65D 51/002** (2013.01 - EP US); **B65D 51/005** (2013.01 - EP US); **B65D 81/24** (2013.01 - EP US);  
**A61J 1/1468** (2015.05 - EP US); **A61K 9/0019** (2013.01 - EP); **A61K 47/10** (2013.01 - EP US); **A61K 47/20** (2013.01 - EP US);  
**A61K 47/26** (2013.01 - EP US)

Citation (search report)

- [I] WO 9828007 A1 19980702 - BIOGEN INC [US], et al
- [I] EP 0736303 A2 19961009 - HOFFMANN LA ROCHE [CH]
- [I] EP 0641567 A1 19950308 - CIBA GEIGY AG [CH]
- [I] WO 9717087 A1 19970515 - GENENTECH INC [US]
- [I] US 5661125 A 19970826 - STRICKLAND THOMAS WAYNE [US]
- [I] WO 9322056 A1 19931111 - MALLINCKRODT MEDICAL INC [US]
- [I] US 2622598 A 19521223 - HAROLD ROSENBLUM

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL HR LT LV MK

DOCDB simple family (publication)

**WO 2004100979 A2 20041125; WO 2004100979 A3 20050519;** AR 044302 A1 20050907; AU 2004237982 A1 20041125;  
AU 2004237982 B2 20100304; AU 2004237982 C1 20180308; BR PI0410679 A 20060620; CA 2523477 A1 20041125; CN 1809376 A 20060726;  
CN 1809376 B 20100428; CY 1115233 T1 20170104; DK 1633388 T3 20140407; EA 008308 B1 20070427; EA 200501692 A1 20060630;  
EP 1633388 A2 20060315; EP 1633388 B1 20140319; EP 2324845 A1 20110525; ES 2471942 T3 20140627; HK 1088558 A1 20061110;  
HR P20140267 T1 20140425; IL 171912 A0 20060410; IL 171912 A 20150226; JP 2007502684 A 20070215; JP 2012096063 A 20120524;  
KR 101084412 B1 20111121; KR 20060009913 A 20060201; MX PA05012191 A 20060208; NO 20055774 D0 20051206;  
NO 20055774 L 20051206; PL 1633388 T3 20140829; PT 1633388 E 20140625; SI 1633388 T1 20140530; UA 91493 C2 20100810;  
US 2007092487 A1 20070426; US 7540382 B2 20090602; US RE43331 E 20120501

DOCDB simple family (application)

**EP 2004050779 W 20040512;** AR P040101607 A 20040511; AU 2004237982 A 20040512; BR PI0410679 A 20040512; CA 2523477 A 20040512;  
CN 200480016991 A 20040512; CY 141100386 T 20140530; DK 04760770 T 20040512; EA 200501692 A 20040512; EP 04760770 A 20040512;  
EP 11152658 A 20040512; ES 04760770 T 20040512; HK 06110556 A 20060921; HR P20140267 T 20140320; IL 17191205 A 20051113;  
JP 2006530185 A 20040512; JP 2012005485 A 20120113; KR 20057021160 A 20040512; MX PA05012191 A 20040512;  
NO 20055774 A 20051206; PL 04760770 T 20040512; PT 04760770 T 20040512; SI 200432149 T 20040512; UA A200510442 A 20040512;  
US 200413151459 A 20040512; US 55646704 A 20040512